News and Announcements
Universal Biosensors Annual General Meeting Presentation
- Published July 13, 2015 11:03AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX Announcement, 9th July 2015
Key Highlights: last 12 months
Acceleration in revenues from blood glucose monitoring
- Quarterly Services Fees up to $2.9m in Q1 FY’15 (up 142% on pcp)
First strip manufacturing revenues from blood coagulation monitoring
- CE Mark and launch of Siemens Xprecia StrideTM Coagulation Analyzer
- Xprecia StrideTM wins international Red Dot Design Award and Australian Design Award
- Cumulative revenues from PT-INR strip manufacturing of $288K (to 31st March 2015)
Continued leveraged investment in new product development
- Around 70% of R&D investment (last 12 months) funded by partners and R&D Tax Rebates,
- Progressing the expansion of our product portfolio;
– UBI-owned PT-INR test for decentralised and home use
– Further POC coagulation tests for Siemens
– Demonstration of immunoassay platform capability
Revenue growth driving improved financial performance
- Two product revenue streams now in play
- Increasing contribution from Product & Services
- Cash breakeven in sight
To read the full presentation, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
